Study part: Rotterdem Symptom Checklist (RSCL) Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Versions (1) ▾
  1. 7/15/17
Copyright Holder:
Uploaded on:

July 15, 2017

No DOI assigned. To request one pleaselog in.
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Rotterdem Symptom Checklist (RSCL) Week 36 Mepolizumab HES NCT00086658

Rotterdem Symptom Checklist (RSCL) Week 36

Rotterdem Symptom Checklist (RSCL)